Literature DB >> 3409892

Non-invasive assessment of infarct reperfusion: the predictive power of the time to peak value of myoglobin, CKMB, and CK in serum.

H A Katus1, K W Diederich, T Scheffold, M Uellner, F Schwarz, W Kübler.   

Abstract

Intravenous thrombolytic therapy has become a routine therapeutic intervention in acute myocardial infarction. In order to evaluate its success in the general hospital community noninvasive methods are needed. Therefore, the effect of infarct reperfusion on the times to peak value of myoglobin, CKMB, and CK were studied in patients with acute myocardial infarction. Recanalization of the occluded coronary artery was achieved by intracoronary infusion of streptokinase in eight patients within 3.5 h, and in 18 patients more than 3.5h after onset of pain. In 10 patients, the coronary artery remained occluded, and in eight patients thrombolysis was not attempted. Analyzing the times to peak value of myoglobin, CKMB, and CK, the probability of correct classification of infarct reperfusion varied between 1 and 0.9, if recanalization was achieved within 3.5 h after onset of pain. The predictive power could be improved further by a combined analysis of the times to peak value of both myoglobin and CK. In cases where reperfusion was achieved more than 3.5 h after the onset of pain, the probability of correct classification of infarct reperfusion varied between 0.99 and 0.05. Among the marker proteins analyzed, myoglobin allowed the earliest and best discrimination between reperfusion or no reperfusion. Thus, by applying the time to peak value analysis, infarct reperfusion can only be predicted reliably if it is achieved early after onset of pain.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3409892     DOI: 10.1093/oxfordjournals.eurheartj.a062551

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  11 in total

1.  Evaluation of coronary artery patency using cardiac markers.

Authors:  Milenko J Tanasijevic
Journal:  J Thromb Thrombolysis       Date:  2005-02       Impact factor: 2.300

2.  Human heart-type cytoplasmic fatty acid-binding protein as an indicator of acute myocardial infarction.

Authors:  K Yoshimoto; T Tanaka; K Somiya; R Tsuji; F Okamoto; K Kawamura; Y Ohkaru; K Asayama; H Ishii
Journal:  Heart Vessels       Date:  1995       Impact factor: 2.037

Review 3.  Novel Invasive and Noninvasive Cardiac-Specific Biomarkers in Obesity and Cardiovascular Diseases.

Authors:  Rajesh Parsanathan; Sushil K Jain
Journal:  Metab Syndr Relat Disord       Date:  2019-10-16       Impact factor: 1.894

4.  Usefulness of combining necrosis and platelet markers in triaging patients presenting with chest pain to the emergency department.

Authors:  V L Serebruany; D J Levine; G V Nair; A F Meister; P A Gurbel
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

5.  Predictive value of ventricular arrhythmias for patency of the infarct-related coronary artery after thrombolytic therapy.

Authors:  A J Six; J H Louwerenburg; J H Kingma; E O Robles de Medina; N M van Hemel
Journal:  Br Heart J       Date:  1991-08

6.  Early diagnosis of acute myocardial infarction by a newly developed rapid immunoturbidimetric assay for myoglobin.

Authors:  J Mair; E Artner-Dworzak; P Lechleitner; B Morass; J Smidt; I Wagner; F Dienstl; B Puschendorf
Journal:  Br Heart J       Date:  1992-11

7.  Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor?

Authors:  R P Gray; J S Yudkin; D L Patterson
Journal:  Br Heart J       Date:  1993-12

Review 8.  An historical approach to the diagnostic biomarkers of acute coronary syndrome.

Authors:  Elisa Danese; Martina Montagnana
Journal:  Ann Transl Med       Date:  2016-05

9.  Fatty-acid-binding protein as a plasma marker for the estimation of myocardial infarct size in humans.

Authors:  J F Glatz; A H Kleine; F A van Nieuwenhoven; W T Hermens; M P van Dieijen-Visser; G J van der Vusse
Journal:  Br Heart J       Date:  1994-02

10.  A Randomized Comparison between Everolimus-Eluting Stent and Cobalt Chromium Stent in Patients with Acute ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention Using Routine Intravenous Eptifibatide: The X-MAN (Xience vs. Multi-Link Stent in Acute Myocardial Infarction) Trial, A Pilot Study.

Authors:  Surya Dharma; Alexander J Wardeh; Sunarya Soerianata; Isman Firdaus; J Wouter Jukema
Journal:  Int J Angiol       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.